Bergen, Norway, 18 November 2020 – Notice is hereby given that an Extraordinary
General Meeting in BerGenBio ASA will be held virtually on 9 December 2020 at
16:00 hours (CET).
The notice, registration form and power of attorney are attached to this
release. The notice will be sent to all registered shareholders and is available
at https://www.bergenbio.com/investors/general-
meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)
All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or the
person he appoints), or to attend the general meeting virtually.
Virtual attendance, advance vote or proxy for the Extraordinary General Meeting
can be registered through the company’s website or VPS Investor Service. All
registered shareholders will receive a reference number and a pin code required
for registration through the company’s website. Reference number and pin code
will be received either by VPS Investor Service or by post depending if the
shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS to save
environment impact.
-Ends-
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused on
developing transformative drugs targeting AXL as a potential cornerstone of
therapy for aggressive diseases, including immune-evasive, therapy resistant
cancers and infectious diseases. The company's proprietary lead candidate,
bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad
Phase II oncology clinical development programme focused on combination and
single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class
functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I
clinical testing. In parallel, BerGenBio is developing a companion diagnostic
test to identify patient populations most likely to benefit from bemcentinib:
this is expected to facilitate more efficient registration trials supporting a
precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For
more information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.